1.85
-0.02
(-1.07%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 1.80 - 1.91 |
| 52 week | 1.23 - 3.73 |
| Open | 1.90 |
| Vol / Avg. | 30,763.00/46,179.00 |
| Mkt cap | 41.63M |
| P/E | - |
| Div/yield | - |
| EPS | -0.78 |
| Shares | 22.50M |
| Beta | 1.97 |
| Inst. own | 16% |
Events
Aug 12, 2013
Q2 2013 EntreMed, Inc. Earnings Release
May 14, 2013
Q1 2013 EntreMed, Inc. Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | - | -234.87% |
| Operating margin | - | -235.36% |
| EBITD margin | - | -233.39% |
| Return on average assets | -49.30% | -80.87% |
| Return on average equity | -53.97% | -954.98% |
| Employees | 7 | - |
| Carbon Disclosure Rating | - | - |
Address
9640 Medical Center Drive
ROCKVILLE, MD 20850
United States - Map
+1-240-8642600 (Phone)
+1-240-8642601 (Fax)
ROCKVILLE, MD 20850
United States - Map
+1-240-8642600 (Phone)
+1-240-8642601 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
EntreMed, Inc. (EntreMed) is a clinical-stage pharmaceutical company. EntreMed's drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 has completed Phase I studies in patients with advanced solid tumors, multiple myeloma and leukemia and is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. The Company�s other product candidates have includes MKC-1, ENMD-1198 and 2-methoxyestrdiol (2ME2, Panzem) for treatment of rheumatoid arthritis. ENMD-2076 is a novel orally-active, Aurora A/angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases.
Officers and directors
| Wei-Wu He Ph.D. | Executive Chairman of the Board | |
| Ken K. Ren | Chief Executive Officer | |
| Dwight L. Bush Sr. | Independent Vice Chairman of the Board | |
| Wong Hu J.D. | Chief Operating Officer, General Counsel, Secretary | |
| Sara B. Capitelli CPA | Vice President - Finance, Principal Accounting Officer | |
| William E. Gannon Jr., M.D. | Vice President - Medical and Regulatory Affairs | |
| Tak W. Mak Ph.D. | Director | |
| James Z. Huang | Independent Director | |
| Jennie C. Hunter-Cevera Ph.D. | Independent Director | |
| Y. Alexander Wu Ph.D. | Independent Director |